We now know that cancer is many different diseases, with great variation even within a
single histological subtype. With the current emphasis on developing personalized …

Cancer has long been a grievous disease complicated by innumerable players aggravating
its cure. Many clinical studies demonstrated the prognostic relevance of the tumor …

Here we report the Simons Genome Diversity Project data set: high quality genomes from
300 individuals from 142 diverse populations. These genomes include at least 5.8 million …

Li-Fraumeni syndrome (LFS) is an autosomal dominantly inherited condition caused by
germline mutations of the TP53 tumor suppressor gene encoding p53, a transcription factor …

The incidence and mortality of various cancers are associated with sex-specific disparities.
Sex differences in cancer epidemiology are one of the most significant findings. Men are …

Patients with cancer carry somatic sequence variants in their tumour in addition to the
germline variants in their inherited genome. Although variants in protein-coding regions …

The tumour suppressor p53 is the most frequently mutated gene in human cancer, with more
than half of all human tumours carrying mutations in this particular gene. Intense efforts to …

For many years, transcription factor Sp1 was viewed as a basal transcription factor and
relegated to a role in the regulation of so‐called housekeeping genes. Identification of Sp1's …

Design of small-molecule inhibitors (MDM2 inhibitors) to block the MDM2–p53 protein–
protein interaction has been pursued as a new cancer therapeutic strategy. In recent years …

The two murine double minute (MDM) family members MDM2 and MDMX are at the center
of an intense clinical assessment as molecular target for the management of cancer. Indeed …